Emergent Biosolutions Inc (EBS)

NYSE
61.57
-0.22(-0.36%)
After Hours
61.57
0.00(0.00%)
- Real-time Data
  • Volume:
    862,270
  • Bid/Ask:
    61.00/61.60
  • Day's Range:
    61.02 - 63.19

EBS Overview

Prev. Close
61.79
Day's Range
61.02-63.19
Revenue
1.71B
Open
61.36
52 wk Range
55.07-136.97
EPS
7.15
Volume
862,270
Market Cap
3.3B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
828,219
P/E Ratio
8.65
Beta
0.97
1-Year Change
-10.16%
Shares Outstanding
53,585,478
Next Earnings Date
Aug 05, 2021
What is your sentiment on Emergent Biosolutions Inc?
or
Market is currently closed. Voting is open during market hours.

Emergent Biosolutions Inc News

Emergent Biosolutions Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuySellSellStrong SellSell
Technical IndicatorsBuyStrong BuyStrong SellSellStrong Sell
SummaryBuyNeutralStrong SellStrong SellStrong Sell

Emergent Biosolutions Inc Company Profile

Emergent Biosolutions Inc Company Profile

Employees
2200

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Read More
  • Watch this glitch to 90$ soon
    0
    • What are the bad news of this stock?
      1
      • CEO dumped a bunch of shares and there was a mixup in their Baltimore plant where they ruined 15 million doses of the J&J vaccine. Google emergent biosolutions, recent article should appear at the top post in last 24 hours. Not sure if I'm in this one yet.
        0
    • time to step in ?
      1
      • Or another fund unwinding after instructions from HQ aka the SEC tapping the prime brokers on the shoulder .... after GMEstop the levraged funds have been told to unwind so there will be more of this using small news and no news to make big moves
        0
        • Someone needed their easter bonus. 15% down is not a normal reaction to this kind of news
          0
          • Any clue about what moved it down in the afterhours?!?
            0
            • The big error with 15 million doses @ the Baltimore plant.
              0
          • I guess somebody knows something we dont :-/
            0
            • A good result and *****!!
              0
              • Some share have no results and the stock skyrocket (Tesla).  I would not buy. When it's the opposite ? It's the moment to buy!
                1
            • what happened here???
              0
              • great earnings but I guess the market is pricing in a "one time" or short term COVID bump? QDEL getting destroyed too.
                0
              • I can not imagine anybody being disappointed by the Q4 2020 results. I think some people do not believe that those results can continue in the future and therefore sell. I  still believe in emergent biolsolution!
                0
            • https://seekingalpha.com/article/4398986-emergent-biosolutions-long-term-thesis-remains-intact
              0
              • Nice to see some movement again
                0
                • Hey Omar... nice to see you here. I invested in ROVI also. I've not bought EBS yet. Thinking of averaging down MRNA and replacing it w EBS. Thoughts?
                  0
                • Michelle Feinstein hey!  EBS was trading around 130 not long ago then it went down after JnJ trials were delayed.  went down into the mid -to-high 70's.  coming back up nicely.  they have contracts with JNJ and Astrazeneca.  also have a nice pipeline.  movement is not like that of Moderna so don't expect the sudden upswings.  you should be up ,somewhat, in Moderna since you bought more at 138.  right now it is 143.  i was going to close my position between 150 -155 but given this new strain i think people will be more willing to get vaccinated.  in a few days we will know whether it is effective against the new strain. lets wait a few hrs to see what happens in the pre-market with moderna.  i kinda like the stability of EBS.
                  0
              • What happen? Why fall?
                1
                • earnings...
                  0
              • what now....above high target all ready
                0
                • courtesy florinthanks a million
                  0
                  • you well come:)
                    0
                • they just signed a million dollar deal will this help?
                  0
                  • Up on Adamis i take it?
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.